Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
about
CUA guideline on adult overactive bladderUrinary retention in female OAB after intravesical Botox injection: who is really at risk?Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.Use of botulinum toxin for voiding dysfunction.Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.Efficacy of onabotulinum toxin A injection in pediatric patients with non-neurogenic detrusor overactivity.Safety issues associated with using medication to treat overactive bladder.Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence-Reply.Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.Individualizing medical treatment of overactive bladder
P2860
Q33665026-4EC525DE-EF61-46F9-B485-971664271621Q33705306-5735905E-37DB-4117-8485-7FFCF498D5ACQ37514596-1EE7A1CF-DFF5-499D-BD18-722C05DE0164Q38679555-A443FA99-1ECD-4BA0-B340-D5DC9C10F14AQ38792373-954FD23C-0C3B-43E9-A669-83D02ADD4B34Q38962547-AADA44C7-2892-445E-95B5-EDDE9AB60740Q40058585-A4F23C47-C607-419A-A235-9538BD6E6B12Q40252069-6C4E71F6-AA71-41BE-B061-6F99325FCDDFQ42339366-EABBA7B3-2E74-496C-8D00-41876D32373FQ51747376-86CDC718-C77D-40C1-ACA4-A8F95DD1EC06Q57298524-166850F1-BEAF-48DC-8590-77D5380BA7EB
P2860
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@en
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@nl
type
label
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@en
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@nl
prefLabel
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@en
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@nl
P2093
P1476
Durable Efficacy and Safety of ...... l Results of a 3.5-Year Study.
@en
P2093
191622-096 Investigators
Andrew Magyar
Brenda Jenkins
Christopher Chapple
David Ginsberg
David Sussman
Dirk De Ridder
Karl-Dietrich Sievert
Peter Sand
Sidney Radomski
P304
P356
10.1016/J.JURO.2016.03.146
P407
P577
2016-03-30T00:00:00Z